ArticleZeitschrift fur Gastroenterologie2013
[Diagnosis of and therapy for hepatocellular carcinoma].
Article in Zeitschrift fur Gastroenterologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.JHEP reports : innovation in hepatology · 2025Article
- [Position paper for the standardized use of transjugular intrahepatic portosystemic shunt (TIPS) in adults].Zeitschrift fur Gastroenterologie · 2025Article
- Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.JHEP reports : innovation in hepatology · 2024Article
- Use of machine learning models for the prognostication of liver transplantation: A systematic review.World journal of transplantation · 2024Article
- [Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)].Zeitschrift fur Gastroenterologie · 2023Article
- Multiparametric Dynamic Ultrasound Approach for Differential Diagnosis of Primary Liver Tumors.International journal of molecular sciences · 2023Article
- Liver Function-How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives.Journal of personalized medicine · 2022Review
- Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.Visceral medicine · 2022Review
- [Local and locoregional treatment of intrahepatic cholangiocarcinoma].Der Radiologe · 2022Review
- Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade.Scientific reports · 2021Article
- Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.European radiology · 2021Article
- Early Detection of Hepatocellular Carcinoma Since the Introduction of the German Clinical Practice Guideline in 2013.Deutsches Arzteblatt international · 2021Article
- Article
- Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).Scientific reports · 2020Observational
- Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany.Journal of clinical medicine · 2020Article
- Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming.Cancer science · 2020Article
- [Interdisciplinary tumor boards in the radiological routine : Current situation based on an online survey in Germany].Der Radiologe · 2020Article
- [Locoregional and local ablative treatment options for liver tumors].Der Internist · 2020Review
- [Sonographic diagnostics of liver tumors].Der Internist · 2020Review
- [Surgical treatment of hepatic tumors-liver resection and transplantation].Der Internist · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
70 authors.
Funding
Abstract
The interdisciplinary guidelines at the S3 level on the diagnosis of and therapy for hepatocellular carcinoma (HCC) constitute an evidence- and consensus-based instrument that is aimed at improving the diagnosis of and therapy for HCC since these are very challenging tasks. The purpose of the guidelines is to offer the patient (with suspected or confirmed HCC) adequate, scientifically based and up-to-date procedures in diagnosis, therapy and rehabilitation. This holds not only for locally limited or focally advanced disease but also for the existence of recurrences or distant metastases. Besides making a contribution to an appropriate health-care service, the guidelines should also provide the foundation for an individually adapted, high-quality therapy. The explanatory background texts should also enable non-specialist but responsible colleagues to give sound advice to their patients concerning specialist procedures, side effects and results. In the medium and long-term this should reduce the morbidity and mortality of patients with HCC and improve their quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.